Tocilizumab as a novel bridging therapy for surgery in dedifferentiated liposarcoma complicated by paraneoplastic leukemoid reaction, severe anemia, and thrombocytopenia: a case report - Top-Institutions - MDSpire

Tocilizumab as a novel bridging therapy for surgery in dedifferentiated liposarcoma complicated by paraneoplastic leukemoid reaction, severe anemia, and thrombocytopenia: a case report

  • By

  • Jinjin Li

  • Ke Li

  • Shanshan Yu

  • Ya Li

  • Jiang Min

  • Zhen Huang

  • Zhengqiang Wei

  • May 5, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    The University of Texas MD Anderson Cancer Center
    The University of Texas MD Anderson Cancer Center

    Houston, TX

    Key Differentiators

    • Oncology
    • Surgical Oncology

  • #2

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, NY

    Key Differentiators

    • Oncology
    • Surgical Oncology

Original Source(s)

Tocilizumab as a novel bridging therapy for surgery in dedifferentiated liposarcoma complicated by paraneoplastic leukemoid reaction, severe anemia, and thrombocytopenia: a case report

  • by Jinjin Li, Ke Li, Shanshan Yu, Ya Li, Jiang Min, Zhen Huang, Zhengqiang Wei

  • May 5, 2026

Related Content

Momelotinib for myelofibrosis: our 14 years of experience with 100 clinical trial patients and recent FDA approval

A Comprehensive Review of Monoclonal Gammopathy of Undetermined Significance

Approximately 3% to 4% of the population over the age of 50 is diagnosed with monoclonal gammopathy of undetermined significance (MGUS). It carries a lifelong risk of progression to multiple myeloma and lymphoma, requiring risk-adapted monitoring by multidisciplinary teams.

Luspatercept for the treatment of anemia in allo-HSCT for patients with hematological diseases